A young male patient with cardiomyopathy associated with human immunodeficiency virus infection in the era of highly active antiretroviral therapy
Abstract
Background: Cardiomyopathy in young people, especially those associated with HIV infection, has been reduced since the era of Highly Active Antiretroviral Therapy (HAART). In the era of post-HAART, manifestations of human immunodeficiency virus (HIV)-associated cardiomyopathy with impaired left ventricular (LV) systolic function are approximately about 1-3% of HIV-infected people. In this case, we presented how to diagnose and appropriately manage such a patient.
Case Illustration: A 27-year-old male patient who works as a health worker came to the emergency room with complaints of shortness of breath; it worsened in the last 2 weeks. He got vital signs: blood pressure 97/60 mmHg, heart rate 118 bpm, respiratory rate 23 tpm, and oxygen saturation 99 % with oxygen supplementation of 8 lpm. Risk factors in patients such as smoking, family history, hypertension, diabetes mellitus, and dyslipidemia were denied. He was diagnosed with HIV on (antiretroviral therapy) ART 3 years ago with risk factors for free sex without protection. The last CD4 value was 796 cells/ul (normal value 637 – 1485). The echocardiography showed all chamber dilatation, global hypokinetic, and a significant decrease in LV systolic function (LVEF 16%). Laboratory examination showed an increase of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) into 6824 pg/mL (normal value <85.8). It was then treated by optimizing HF therapy continue HIV therapy.
Conclusion: In HIV patients who have fallen into heart failure, a proper diagnosis using relevant tools could be a reference for clinicians to make the right decision. Prompt treatment combination of optimal HF therapy and HIV therapy are becoming the keys to the treatment.
Keywords
Full Text:
PDFReferences
Remick J, Georgiopoulou V, Marti C, et al. Heart failure in patients with human immunodeficiency virus infection: Epidemiology, pathophysiology, treatment, and future research. Circulation. 2014;129(17):1781-1789. doi:10.1161/CIRCULATIONAHA.113.004574
Lumsden RH, Bloomfield GS. The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds. Biomed Res Int. 2016;2016. doi:10.1155/2016/8196560
Thiene G, Corrado D, Basso C. Revisiting definition and classification of cardiomyopathies in the era of molecular medicine. Eur Heart J. 2008;29(2):144-146. doi:10.1093/eurheartj/ehm585
Ichael GM, Elker F, Hompson IET, et al. Volume 342 Number 15 · 1077 UNDERLYING CAUSES AND LONG-TERM SURVIVAL IN PATIENTS WITH INITIALLY UNEXPL AINED CARDIOMYOPATHY UNDERLYING CAUSES AND LONG-TERM SURVIVAL IN PATIENTS WITH INITIALLY UNEXPLAINED CARDIOMYOPATHY A BSTRACT.
Berzingi C, Chen F, Finkel MS. P38 MAP kinase inhibitor prevents diastolic dysfunction in rats following HIV gp120 injection in vivo. Cardiovasc Toxicol. 2009;9(3):142-150. doi:10.1007/s12012-009-9047-1
Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-1816. doi:10.1161/CIRCULATIONAHA.106.174287
Islam M, Velasquez B. A Case of Severe HIV-Associated Cardiomyopathy: Highlighting Susceptibility, Despite a Reassuring CD4. Chest. 2015;148(4):71A. doi:10.1378/chest.2275633
Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. The Lancet. 2017;390(10092):400-414. doi:10.1016/S0140-6736(16)31713-5
Towbin JA, Jefferies JL. Cardiomyopathies due to left ventricular noncompaction, mitochondrial and storage diseases, and inborn errors of metabolism. Circ Res. 2017;121(7):838-854. doi:10.1161/CIRCRESAHA.117.310987
Togatorop B, Soesanto AM. • Januari-Maret. Jurnal Kardiologi Indonesia J Kardiol Indones. 2012;33(1):55-62.
Shafer’ RW, Vuitton DA. Highly Active Antiretroviral Therapy (HAART) for the Treatment of Infection with Human Immunodeficiency Virus Type 1. http://www.hivatis.org
KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA.
DOI: https://doi.org/10.21776/ub.hsj.2024.005.04.17
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Zainal Fathurohim, Heny Martini
This work is licensed under a Creative Commons Attribution 4.0 International License.